GH Research (NASDAQ:GHRS) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS

GH Research (NASDAQ:GHRS) announced its earnings results on Friday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.13, FiscalAI reports.

GH Research Stock Up 5.0%

GHRS traded up $0.93 on Friday, reaching $19.42. The company’s stock had a trading volume of 390,056 shares, compared to its average volume of 303,355. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -19.41 and a beta of 1.31. GH Research has a fifty-two week low of $12.04 and a fifty-two week high of $31.44. The stock has a 50 day moving average of $22.48 and a two-hundred day moving average of $21.63.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of GH Research from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. New Street Research set a $65.00 price objective on GH Research in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating on shares of GH Research in a research note on Monday, August 10th. Finally, Stifel Nicolaus set a $38.00 price target on shares of GH Research in a report on Friday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.36.

About GH Research

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.